Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Secretory carcinoma of the lacrimal gland].

Journal francais d'ophtalmologie·2025
Same author

Zero and ultra-short echo time and contrast-medium injection at 3-T to detect Achilles enthesitis and distinguish rheumatismal vs mechanical etiologies.

Clinical radiology·2025
Same author

Role of viral coinfection in post-pandemic invasive Group A streptococcal infections in adults, a nation-wide cohort study (iGASWISS).

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2025
Same author

[The impact of bronchoalveolar lavage in patients intubated for COVID-19].

Revue des maladies respiratoires·2025
Same author

Individual mHLA-DR trajectories in the ICU as predictors of early infections following liver transplantation: a prospective observational study.

Critical care (London, England)·2025
Same author

Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients.

ESMO open·2024

Related Experiment Video

Updated: Jul 3, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

[Combination therapy in chronic hepatitis B].

C Fournier1, F Zoulim

  • 1INSERM, U871, 151, cours Albert Thomas, 69003 Lyon, France.

Gastroenterologie Clinique Et Biologique
|July 30, 2008
PubMed
Summary
This summary is machine-generated.

Hepatitis B virus (HBV) genome variability complicates treatment, leading to drug resistance. Combining nucleoside analogs early or de novo may offer benefits, but clinical trials are needed to confirm efficacy.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Area of Science:

  • Virology
  • Hepatology
  • Pharmacology

Context:

  • Hepatitis B virus (HBV) infection presents complex viral quasi-species and evolution.
  • Antiviral therapy is challenged by infected cell persistence, driving drug-resistant strain selection.
  • Nucleoside analogs with complementary resistance profiles guide add-on strategies for virologic breakthrough.

Purpose:

  • To explore the complexities of HBV genome variability and its impact on antiviral therapy.
  • To evaluate the rationale and trends in combination antiviral strategies for HBV.
  • To determine the added benefit of de novo nucleoside analog combinations versus early add-on strategies.

Summary:

  • HBV genome variability drives viral quasi-species complexity and evolution during infection.
  • Drug resistance during antiviral therapy is influenced by persistent infected cells.
  • Current trends favor earlier antiviral addition or de novo combinations, especially with partial virologic response or high resistance risk.

Impact:

  • Clinical trials are essential to compare de novo combination versus early add-on strategies for HBV treatment.
  • De novo combination is recommended for patients with compromised liver function or complex viral quasi-species.
  • Understanding HBV evolution and resistance is crucial for optimizing antiviral therapies and patient outcomes.